Loading...
Market
What will be the impact of Pfizer's gene therapy for Hemophilia A on annual bleeding episodes in patients by December 31, 2025?
2
Resolution / Starting Odds
Reduction by <25% • 25%
Reduction by 25-50% • 25%
Reduction by 50-75% • 25%
Reduction by >75% • 25%
Clinical trial follow-up studies and medical journals
Story
Pfizer's $PFE Gene Therapy Shows Positive Results in Hemophilia A Late-Stage Phase 3 Study
Jul 24, 2024, 10:49 AM
Pfizer has announced positive topline results from its Phase 3 study of a gene therapy candidate for Hemophilia A. The therapy, developed in collaboration with Sangamo Therapeutics, aims to reduce bleeding episodes in patients with the severe bleeding disorder. The study's success marks a significant milestone in the treatment of Hemophilia A, offering hope for improved management of the condition. Pfizer's stock symbol is $PFE, and the therapy met its goal in a pivotal late-stage trial.
View original story
Similar markets
Less than 1,000 • 25%
1,000 to 5,000 • 25%
5,000 to 10,000 • 25%
More than 10,000 • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increase by more than 10% • 25%
Increase by 0% to 10% • 25%
No significant change • 25%
Decrease • 25%
Yes • 50%
No • 50%
Successful with significant efficacy • 25%
Successful with moderate efficacy • 25%
Unsuccessful due to adverse effects • 25%
Unsuccessful due to lack of efficacy • 25%
No new competitors • 25%
1-2 new competitors • 25%
3-4 new competitors • 25%
5+ new competitors • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 50% efficacy • 25%
50-69% efficacy • 25%
70-89% efficacy • 25%
90% or higher efficacy • 25%